PRESS RELEASES

CEVEC and UCB sign agreement for the use of CEVEC’s ELEVECTA® AAV manufacturing technology in Gene Therapy

  • The ELEVECTA® Technology produces Stable Producer Cell Lines designed to enable fully scalable, high-performance AAV vector production
  • Under the agreement, CEVEC grants UCB rights and options to the ELEVECTA® Technology for the research, development and manufacturing of AAV gene therapy products

Cologne, Germany, September 7, 2021

CEVEC closes growth financing round to serve strong demand in viral vector technologies for cell and gene therapies

  • With its highly scalable Adenovirus and AAV production technologies, CEVEC provides cutting-edge manufacturing solutions for two of the most widely used gene therapy vectors
  • Funding will expand cell line development capacities for ELEVECTA® stable AAV
    producer cell lines
  • With ELEVECTA® currently being implemented in a second host cell type, an even stronger demand is expected

Cologne, Germany, July 27, 2021

CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP® Technology in anti-tumor cell therapies

  • CARISMA receives full rights to use the CAP® Technology for the production of adenoviral vectors across their whole portfolio of cell therapies for oncology applications
  • CEVEC’s unique CAP® cells are specifically designed for highly scalable, RCA-free adenoviral vector manufacturing in suspension bioreactors
  • The agreement supports CARISMA’s development of novel CAR-macrophage immunotherapies, a first-of-its-kind approach to the treatment of solid tumors

Cologne, Germany and Philadelphia, PA, February 2, 2021

CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA® in gene therapy

  • Under the agreement CEVEC grants Biogen rights to its proprietary ELEVECTA® Technology for manufacturing of gene therapy products
  • ELEVECTA® stable producer cell lines enable fully scalable, helper virus-free AAV vector production in suspension bioreactors

Cologne, Germany, January 8, 2021

CEVEC signs agreement with Roche for the use of CEVEC’s ELEVECTA® Technology in gene therapy

  • Agreement will allow Roche to use CEVEC’s unique and proprietary ELEVECTA® Technology for AAV vector manufacturing
  • The ELEVECTA® Stable Producer Cell Lines are designed to enable fully scalable, high-performance biopharmaceutical industry

Cologne, Germany, November 10, 2020

CEVEC and Rznomics sign license agreement for the use of CAP® Technology in manufacturing of adenoviral vectors

  • Rznomics will use the technology for gene therapies based on their proprietary trans-splicing ribozyme technology targeting various cancer indications
  • CEVEC’s unique CAP® cell line enables by design the efficient production of high-quality adenoviral vectors

Cologne, Germany and Yongin, Korea, October 19, 2020

CEVEC Announces the Launch of the ELEVECTA® Platform – the Stable Producer Cell Line Technology for AAV Gene Therapy Vectors

  • ELEVECTA® takes viral vector manufacturing to the next level to serve the rapidly growing market of gene therapy applications
  • Growing serum-free in suspension, ELEVECTA® producer cell lines enable fully scalable high-performance AAV vector production based on standardized processes widely used in industry for monoclonal antibody production
  • With all components stably integrated into one cell, the ELEVECTA® technology provides large scale AAV production without expensive cGMP-grade plasmids and complex transient transfection steps

 Cologne, Germany, April 28, 2020

CEVEC signs license agreement for the development and commercialization of exosomes for therapeutic use

  • Agreement with Evox Therapeutics supports the utility of CAP® technology in the production of exosomes
  • Exosomes offer distinct advantages as highly effective drug carriers
  • Evox Therapeutics intends to develop CAP®-derived exosomes for several disease areas and indications

Cologne, Germany, April 16, 2020

© CEVEC Pharmaceuticals GmbH 2021